Grant of Share Options
Trellus Health plc announced the grant of options over 807,541 ordinary shares to Chairman Kevin Murphy, with an exercise price of 0.525p per share, aligning with the company's existing share option plan and a recent loan note. These options vest in twelve quarterly instalments over 39 months and are subject to lock-in provisions and customary leaver clauses, with independent directors deeming the award fair and beneficial for shareholder alignment.
Select text to share a quote on X · sign in to keep highlights & notes in your TRLS notes
LONDON, U.K. AND NEW YORK, U.S. (19 January 2026). Trellus Health® plc (AIM: TRLS), a healthcare company delivering Trellus Elevate®, a digital platform that integrates data analytics with personalised, scientifically proven resilience programs and value-based solutions to manage complex chronic conditions, announces that the Board has granted options over a total of 807,541 ordinary shares of £0.0006 in the capital of the Company (the "Share Options") to Kevin Murphy, Chairman of the Company (the "Option Holder").
The Share Options, which have been issued in line with the Company's existing share option plan (the "Option Plan"), have an exercise price of 0.525p per ordinary share. This is in line with the exercise price of the Loan Note, entered into with Mount Sinai on November 24, 2025. The Share Options are subject to lock-in provisions, being 12 months from the date the Share Options are exercised.
The Share Options vest and become exercisable in twelve (12) equal quarterly instalments (rounded up to the nearest whole share) thereafter of which the first instalment shall vest three months after the grant date and the twelfth shall vest 39 months after the vesting commencement date.
The Share Options are subject to the rules of the Option Plan and the relevant award documentation, including customary good leaver and bad leaver provisions.
The independent directors consider that the award is fair and reasonable insofar as the Company's shareholders are concerned and believe it appropriately aligns the Chairman's interests with those of shareholders.
| a) | Name | Kevin Laurence Murphy |
| 2 | Reason for the notification | |
| a) | Position/status | Chairman |
| b) | Initial notification /Amendment | Initial notification |
| a) | Name | Trellus Health plc |
| b) | LEI | 2138002FHWJSR8YKP295 |
| a) | Description of the financial instrument, type of instrument | Options over ordinary shares of £0.0006 each in the Company |
| Identification code | GB00BNNFM402 | |
| b) | Nature of the transaction | Grant of options over shares |
| c) | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| £0.00525 exercise price | 807,541 | |
| d) | Aggregated information | |
| - Aggregated volume | N/A | |
| - Price | N/A | |
| e) | Date of the transaction | 16 January 2026 |
| f) | Place of the transaction | Outside of trading venue - off market |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.